Glaukos Co. (NYSE:GKOS) Insider Tomas Navratil Sells 3,416 Shares

Glaukos Co. (NYSE:GKOS) insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Glaukos Stock Performance

NYSE:GKOS opened at $161.30 on Thursday. The firm has a market capitalization of $8.89 billion, a PE ratio of -53.41 and a beta of 1.04. The firm’s fifty day simple moving average is $152.65 and its 200 day simple moving average is $139.03. Glaukos Co. has a 1 year low of $83.90 and a 1 year high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Wall Street Analyst Weigh In

Several research analysts have weighed in on GKOS shares. Truist Financial upped their price objective on shares of Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. UBS Group assumed coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective for the company. Wells Fargo & Company boosted their target price on Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. JPMorgan Chase & Co. raised their price target on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $140.00 to $200.00 in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $159.42.

Institutional Trading of Glaukos

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Glaukos by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier’s stock worth $895,887,000 after buying an additional 101,838 shares during the period. Wellington Management Group LLP grew its stake in shares of Glaukos by 294.5% in the third quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after acquiring an additional 1,630,270 shares during the last quarter. State Street Corp increased its position in Glaukos by 5.3% during the third quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after acquiring an additional 98,109 shares during the period. Invesco Ltd. raised its stake in Glaukos by 4.9% during the 4th quarter. Invesco Ltd. now owns 1,458,635 shares of the medical instruments supplier’s stock valued at $218,708,000 after purchasing an additional 68,310 shares during the last quarter. Finally, Primecap Management Co. CA boosted its holdings in Glaukos by 2.0% in the 3rd quarter. Primecap Management Co. CA now owns 1,245,185 shares of the medical instruments supplier’s stock valued at $162,223,000 after purchasing an additional 24,370 shares during the period. Institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.